Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacob Rubin

Cardiovascular Disease Sherman Oaks, CA Medical Doctor

NPI 1437151180 CMS profile 489687

4940 Van Nuys Blvd, Suite 200, Sherman Oaks, CA 91403

Open in the dashboard

General payments

$7,876

353 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Rubin of Sherman Oaks, CA is reported in the CMS Open Payments database as having received $7,876 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,827 72
2024 General $1,336 59
2023 General $1,337 67
2022 General $1,045 60
2021 General $991 48
2020 General $487 16
2019 General $852 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Rubin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jacob Rubin were reported at $1,827. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jacob Rubin Cardiovascular Disease median Middle half National median
2019 $852 $450 $127–$1,392 $163
2020 $487 $242 $77–$751 $114
2021 $991 $335 $101–$1,037 $132
2022 $1,045 $395 $121–$1,211 $149
2023 $1,337 $443 $136–$1,283 $160
2024 $1,336 $450 $136–$1,323 $164
2025 $1,827 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $984 54 payments
  2. Abbott Laboratories $803 11 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $780 49 payments
  4. AstraZeneca Pharmaceuticals LP $698 37 payments
  5. Pfizer Inc. $596 40 payments
  6. Edwards Lifesciences Corporation $498 13 payments
  7. Amgen Inc. $482 24 payments
  8. Merck Sharp & Dohme Corporation $478 24 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $453 14 payments
  10. E.R. Squibb & Sons, L.L.C. $366 19 payments
  11. Other $1,738 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,805 349 payments
  2. Education $71 4 payments
Products named General payments · program years 2019–2025
  1. LifeVest $780 49 payments
  2. LEQVIO $614 34 payments
  3. VERQUVO $561 27 payments
  4. VYNDAQEL $438 30 payments
  5. SAPIEN 3 Ultra RESILIA $407 10 payments
  6. Repatha $388 20 payments
  7. TactiCath Quartz CFA Catheter $333 2 payments
  8. ENTRESTO Cardiovascular $331 18 payments
  9. XARELTO $308 16 payments
  10. ENTRESTO Cardiology/Vascular Diseases $305 15 payments
  11. Other $4,247 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,505

Median for Cardiology: 2,533

Drug cost

$389,594

Median for Cardiology: $485,213

Branded share of claims

27.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 92 $82,799
Repatha Sureclick Evolocumab Brand 100 $72,743
Eliquis Apixaban Brand 68 $62,865
Entresto Sacubitril/Valsartan Brand 35 $39,248
Xarelto Rivaroxaban Brand 41 $36,448
Multaq Dronedarone Hcl Brand 27 $30,545
Mounjaro Tirzepatide Brand 11 $13,672
Praluent Pen Alirocumab Brand 26 $12,502
Isosorbide Dinitrate Generic 21 $11,109
Valsartan Generic 186 $3,610

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$576,675

Medicare's payments for the services billed

Medicare patients

1,098

Average age 78

Services billed

6,309

591 women, 507 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Ischemic heart disease 62%
Diabetes 57%
Heart failure 51%
Depression 46%
Chronic kidney disease 44%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $158
$158 92 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $132
$132 — —
VYNDAQEL
  • PFIZER INC. $129
$129 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $93
$93 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record